Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7039145
Reference Type
Journal Article
Title
A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance
Author(s)
Perrio, MJ; Wilton, LV; Shakir, SA; ,
Year
2007
Is Peer Reviewed?
1
Journal
Drug Safety
ISSN:
0114-5916
EISSN:
1179-1942
Volume
30
Issue
8
Page Numbers
681-695
Language
English
PMID
17696581
DOI
10.2165/00002018-200730080-00005
Abstract
Monitoring was required for the introduction of non-chlorofluorocarbon (CFC) propellants in metered dose inhalers (MDIs) to ensure that there were no unexpected adverse events due to the new products. A postmarketing surveillance study has been conducted to evaluate the introduction of the MDI Seretide Evohaler (hydrofluoroalkane-134a inhaler containing salmeterol and fluticasone propionate).
Keywords
Adult; Aerosol Propellants/adverse effects; Albuterol/adverse effects/analogs & derivatives; Androstadienes/adverse effects; Asthma/drug therapy; Bronchodilator Agents/adverse effects; Drug Combinations; England; Fluticasone-Salmeterol Drug Combination; Hydrocarbons, Fluorinated/adverse effects; Metered Dose Inhalers/adverse effects; Middle Aged; Pregnancy; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive/drug therapy
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity